CHU de Bicêtre, UNSIV (neurovascular stroke unit)
Le Kremlin-Bicêtre, 94270, France
NCT Number: NCT03230149
FD is pan-ethnic. Its reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease. Indeed, recently, in addition with affected males FD developing a "classic" phenotype, " cardiac variant " and " renal variant " have been reported for FD patients with predominant or exclusive cardiac or renal involvement. " Neurologic variant " could exist.
Nervous system can be affect by FD leading to cerebrovascular diseases (ischemic or haemorrhagic strokes, TIA (Transient Ischemic Attacks) or peripheral neuropathy (acroparesthesias and pain).
Aims will be to determine the prevalence of Fabry disease in patients with stroke or small fiber neuropathy, and their characteristics
Looking for future studies?
Notify Me18 year–60 year
All sexes
Observational
Le Kremlin-Bicêtre, 94270, France
FD is pan-ethnic. Its reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease. Indeed, recently, in addition with affected males FD developing a "classic" phenotype, " cardiac variant " and " renal variant " have been reported for FD patients with predominant or exclusive cardiac or renal involvement. " Neurologic variant " could exist.
Nervous system can be affect by FD leading to cerebrovascular diseases (ischemic or haemorrhagic strokes, TIA (Transient Ischemic Attacks) or peripheral neuropathy (acroparesthesias and pain).
The investigators aimed to evaluate the frequency of FD in a cohort of stroke patients in tertiary stroke centers in consecutively recruited patients under 60 yo. The investigators will include patients with so-called cryptogenic stroke but also stroke patients due to large artery atherosclerosis, cardioembolism, and small-vessel occlusion. The investigators will also study the clinical and radiological characteristic of stroke patients due to FD, and will compare these data with those from patients without FD, supported by biochemical and genetic findings.
In SFN patients,the investigators aimed to screen for FD in our tertiary national center for peripheral neuropathies, in addition to others diseases or affections, to evaluate the frequency of FD in a large cohort of SFN patients, and describe the clinical phenotype of SFN in FD patients compared to other ones.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.
Time frame: at the end of the study (an average of 2 years)
number of patients with fabry disease in the cohort of stroke patients (1000 patients)
Time frame: at the end of the study (an average of 2 years)
number of patients with fabry disease in the cohort of small fiber neuropathy patients (100 patients)
Assistance Publique - Hôpitaux de Paris
Other
Acronym: FABRY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02985710
Brain Diseases, Brain Diseases, Metabolic
Boston, Massachusetts, United States
View Trial DetailsNCT00084084
Brain Diseases, Brain Diseases, Metabolic
Tucson, Arizona, United States
View Trial DetailsNCT00413595
Brain Diseases, Brain Diseases, Metabolic
Graz, Austria
View Trial DetailsNCT00106912
Brain Diseases, Brain Diseases, Metabolic
Bethesda, Maryland, United States
View Trial Details